- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma launches cough syrup Chericof 12 in India
Mumbai: Pharma major, Sun Pharmaceutical Industries Ltd., today announced the launch of a novel formulation in cough management - Chericof 12 (Dextromethorphan Hydrobromide 30 mg and Chlorpheniramine Maleate 4 mg) in India.
Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug.
Chericof 12 is approved for patients of age group six years and above. All cough syrups generally give relief for 6-8 hours, and hence a patient has to take it three to four times a day. Frequent dosing often leads to patient inconvenience and non-adherence to follow the regimen, which may compromise the efficacy of the medication and disturb the daily lifestyle.
As per a study, a twice-a-day dosing regimen was associated with significantly better compliance in 70% of patients than threetimes a day (52%) and four-times a day (42%) dosing regimen, respectively . The Polistirex technology used in Chericof 12 provides sustained release of the medicine in the body, thus offering up to 12 hour relief to patients with twice-daily dosage.
Kirti Ganorkar, CEO – India Business, Sun Pharma said "At Sun Pharma, we always endeavour to introduce differentiated medicines that enhance convenience or solve patients' problems, thus helping them to cope better with their ailments. The Polistirex technology used in Chericof 12 helps in improving patient compliance and avoids the need for frequent dosing."
Polistirex Technology involves the complexation of two drugs, Dextromethorphan Hydrobromide and Chlorpheniramine maleate with resins. The resin granules of both drugs are added in suspension to form Chericof 12. Complexation of drugs with polistirex not only provides sustained release but also masks the bitter taste making it more palatable. Chericof 12 is a prescription product and should only be taken on the doctor's advice.
Read also: Sun Pharma introduces nutrition bar Revital NXT in India
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751